Table 2.
Confirmed best overall response rates according to RECIST v1.1 (FAS).
Atezolizumab + bevacizumab | |
---|---|
N = 40 | |
Best overall response, n (%) | |
CR | 1 (2.5) |
PR | 17 (42.5) |
SD | 8 (20.0) |
PD | 13 (32.5) |
Not evaluable | 1 (2.5) |
ORR (CR+PR), n (%) | 18 (45.0) |
(95% Cl) | (29.3–61.5) |
Disease control rate (CR+PR+SD), n (%) | 26 (65.0) |
(95% Cl) | (48.3–79.4) |
DOR, months (95% Cl) | 12.5 (5.5–NR) |
Abbreviations: PD, progressive disease; SD, stable disease.